Circulating miRNA-29b and Sclerostin Levels Correlate with Coronary Artery Calcification and Cardiovascular Events in Maintenance Hemodialysis Patients
Table 1
Clinical and biochemical characteristics of MHD patients among the CAC (<100), CAC (100–400), and CAC (>400) groups.
Item
CAC (<100) n = 44
CAC (100–400) n = 27
CAC (>400) n = 34
Age (year)
56.27 ± 11.48
57.89 ± 9.53
62.26 ± 9.10
Gender/male (%)
29 (65.91%)
15 (55.56%)
19 (55.88%)
Smoking history (%)
18 (40.91%)
11 (40.74%)
14 (41.18%)
Hypertension (%)
32 (72.73%)
24 (88.89%)
31 (91.18%)
Diabetes mellitus (%)
9 (20.45%)
8 (29.63%)
15 (44.12%)
Dialysis duration (month)
31.55 ± 15.34
41.05 ± 16.18
51.88 ± 15.18
Kt/v
1.36 ± 0.21
1.34 ± 0.25
1.31 ± 0.24
BMI (kg/m2)
22.32 ± 2.89
22.44 ± 2.45
23.34 ± 2.66
MAP (mmHg)
107.52 ± 11.65
111.91 ± 13.13
116.21 ± 13.30
Hb (g/L)
120.76 ± 12.12
118.87 ± 11.09
119.84 ± 13.28
TC (mmol/L)
3.84 ± 1.07
3.87 ± 0.98
3.79 ± 0.99
TG (mmol/L)
2.11 ± 0.94
2.23 ± 0.68
2.29 ± 1.05
HDL-C (mmol/L)
1.04 ± 0.31
0.94 ± 0.36
0.92 ± 0.22
LDL-C (mmol/L)
2.09 ± 0.91
2.12 ± 0.79
2.06 ± 0.90
UA (umol/L)
388.95 ± 124.44
430.20 ± 89.75
428.37 ± 107.84
Alb (g/L)
41.23 ± 3.82
40.72 ± 3.42
42.46 ± 7.18
hs-CRP (mg/L)
5.88 ± 1.99
8.22 ± 1.79
9.79 ± 2.69
ALP (U/L)
77.17 ± 25.17
82.66 ± 27.12
91.12 ± 29.67
Calcium (mmol/L)
2.43 ± 0.23
2.48 ± 0.32
2.53 ± 0.32
Phosphate (mmol/L)
1.75 ± 0.54
2.05 ± 0.63
2.26 ± 0.49
iPTH (pg/ml)
187.48 (79.61, 346.33)
223.77 (52.06, 364.05)
331.43 (138.54, 609.24)
∗indicates that the data are statistically significant compared with CAC (<100) group. # reveals that the data are statistically significant compared with CAC (100–400) group.
